🏥
US drug shortages stem from poor regulation, not China
🏥 Health

US drug shortages stem from poor regulation, not China

In 2025, the US recorded 216 active drug shortages affecting access to life-saving medications. The author argues that framing the crisis as a US-China competition issue distracts from the real cause: inadequate regulation of a pharmaceutical industry that prioritises profit over public health. Without systemic regulatory reform, supply chain vulnerabilities will persist regardless of trade policy.

Comments

No comments yet